| Symbol | DNLI |
|---|---|
| Name | DENALI THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 161 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 650 866-8548 |
| Fax | — |
| — | |
| Website | https://www.denalitherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001714899 |
| Description | Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The companys development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinsons disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. Additional info from NASDAQ: |
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
Read more(10% Negative) DENALI THERAPEUTICS INC. (DNLI) Announces Delay in medicines Trials for rare pediatric diseases Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreDenali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
Read moreDirector FLATLEY JAY T 🟢 acquired 25.6K shares (1 derivative) of Denali Therapeutics Inc. (DNLI) at $19.66 Transaction Date: Jun 03, 2026 | Filing ID: 000005
Read moreDirector Klein Peter S 🟢 acquired 25.6K shares (1 derivative) of Denali Therapeutics Inc. (DNLI) at $19.66 Transaction Date: Jun 03, 2026 | Filing ID: 000002
Read moreDirector Krognes Steve E. 🟢 acquired 25.6K shares (1 derivative) of Denali Therapeutics Inc. (DNLI) at $19.66 Transaction Date: Jun 03, 2026 | Filing ID: 000015
Read moreDirector Schenkein David P 🟢 acquired 25.6K shares (1 derivative) of Denali Therapeutics Inc. (DNLI) at $19.66 Transaction Date: Jun 03, 2026 | Filing ID: 000004
Read moreDirector Thornberry Nancy 🟢 acquired 25.6K shares (1 derivative) of Denali Therapeutics Inc. (DNLI) at $19.66 Transaction Date: Jun 03, 2026 | Filing ID: 000002
Read moreDirector Van Hauwermeiren Timothy 🟢 acquired 25.6K shares (1 derivative) of Denali Therapeutics Inc. (DNLI) at $19.66 Transaction Date: Jun 03, 2026 | Filing ID: 000003
Read moreDirector Cook Jennifer E. 🟢 acquired 25.6K shares (1 derivative) of Denali Therapeutics Inc. (DNLI) at $19.66 Transaction Date: Jun 03, 2026 | Filing ID: 000002
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07354724 | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL95… | Phase1 | Late-onset Pompe Disease | Recruiting | 2026-05-12 | 2028-08-01 | ClinicalTrials.gov |
| NCT07328451 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Alzheimer Disease, Early Onset | Recruiting | 2026-01-30 | 2027-02-01 | ClinicalTrials.gov |
| NCT06602193 | Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associ… | Phase2 | Parkinson Disease | Active_Not_Recruiting | 2024-10-24 | 2028-02-28 | ClinicalTrials.gov |
| NCT06281158 | A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14… | Phase1 | Healthy Volunteers | Completed | 2024-03-01 | 2024-04-30 | ClinicalTrials.gov |
| NCT06181136 | Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA … | Phase1 | Mucopolysaccharidosis Type IIIA | Active_Not_Recruiting | 2023-12-07 | 2028-08-01 | ClinicalTrials.gov |
| NCT06075537 | An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tivid… | Phase2 | Mucopolysaccharidosis II | Enrolling_By_Invitation | 2023-09-20 | 2027-06-01 | ClinicalTrials.gov |
| NCT05842941 | HEALEY ALS Platform Trial - Regimen G DNL343 | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2023-05-24 | 2024-10-29 | ClinicalTrials.gov |
| NCT05523206 | A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysacchari… | — | Mucopolysaccharidosis III-A | Completed | 2022-09-27 | 2025-01-28 | ClinicalTrials.gov |
| NCT05418673 | A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-S… | Phase3 | Parkinson Disease | Terminated | 2022-08-26 | 2023-07-27 | ClinicalTrials.gov |
| NCT05371613 | A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs I… | Phase2 | Mucopolysaccharidosis II | Recruiting | 2022-07-21 | 2027-12-01 | ClinicalTrials.gov |
| NCT05450549 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Healthy Participant | Completed | 2022-07-14 | 2023-06-08 | ClinicalTrials.gov |
| NCT05262023 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Frontotemporal Dementia | Active_Not_Recruiting | 2022-02-01 | 2028-11-01 | ClinicalTrials.gov |
| NCT05119790 | A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite I… | Phase1 | Healthy Volunteers | Completed | 2021-08-27 | 2021-11-05 | ClinicalTrials.gov |
| NCT05006352 | A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL3… | Phase1 | Amyotrophic Lateral Sclerosis | Completed | 2021-08-11 | 2024-06-05 | ClinicalTrials.gov |
| NCT05005338 | A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy … | Phase1 | Healthy Volunteers | Completed | 2021-07-28 | 2021-09-23 | ClinicalTrials.gov |
| NCT04581772 | A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunte… | Phase1 | Healthy Volunteers | Completed | 2020-12-23 | 2021-06-04 | ClinicalTrials.gov |
| NCT04251026 | A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syn… | Phase1 | Mucopolysaccharidosis II | Active_Not_Recruiting | 2020-07-16 | 2031-02-01 | ClinicalTrials.gov |
| NCT04268784 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Healthy Volunteers | Completed | 2020-02-20 | 2021-08-03 | ClinicalTrials.gov |
| NCT04007536 | A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in H… | — | Mucopolysaccharidosis II | Completed | 2019-10-23 | 2024-03-01 | ClinicalTrials.gov |
| NCT03757325 | Study to Evaluate DNL747 in Subjects With Alzheimer's Disease | Phase1 | Alzheimer Disease | Completed | 2019-02-13 | 2019-12-05 | ClinicalTrials.gov |
| NCT03710707 | Study to Evaluate DNL201 in Subjects With Parkinson's Disease | Phase1 | Parkinson Disease | Completed | 2018-12-04 | 2019-12-06 | ClinicalTrials.gov |
| NCT04557800 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Healthy Volunteers | Completed | 2017-11-16 | 2021-02-19 | ClinicalTrials.gov |
| NCT04551534 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Healthy Volunteers | Completed | 2017-06-01 | 2018-08-08 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Alzheimer Disease, Early Onset | RECRUITING | NCT07328451 |
| DNL628 | Other | Phase PHASE1 | Alzheimer Disease, Early Onset | RECRUITING | NCT07328451 |
| DNL952 | Other | Phase PHASE1 | Late-onset Pompe Disease | RECRUITING | NCT07354724 |
| tividenofusp alfa | Other | Phase PHASE2 | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT06075537 |
| BIIB122-Matching Placebo | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06602193 |
| BIIB122 225 mg | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06602193 |
| BIIB122-Matching Placebo | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06602193 |
| BIIB122 225 mg | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06602193 |
| BIIB122-Matching Placebo | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06602193 |
| BIIB122 225 mg | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06602193 |
| BIIB122-Matching Placebo | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06602193 |
| BIIB122 225 mg | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06602193 |
| BIIB122-Matching Placebo | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06602193 |
| BIIB122 225 mg | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06602193 |
| BIIB122-Matching Placebo | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06602193 |
| BIIB122 225 mg | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06602193 |
| BIIB122-Matching Placebo | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06602193 |
| BIIB122 225 mg | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06602193 |
| DNL952 | Other | Phase PHASE1 | Late-onset Pompe Disease | RECRUITING | NCT07354724 |
| tividenofusp alfa | Other | Phase PHASE2 | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT06075537 |
| DNL952 | Other | Phase PHASE1 | Late-onset Pompe Disease | RECRUITING | NCT07354724 |
| tividenofusp alfa | Other | Phase PHASE2 | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT06075537 |
| DNL952 | Other | Phase PHASE1 | Late-onset Pompe Disease | RECRUITING | NCT07354724 |
| tividenofusp alfa | Other | Phase PHASE2 | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT06075537 |
| DNL952 | Other | Phase PHASE1 | Late-onset Pompe Disease | RECRUITING | NCT07354724 |
| tividenofusp alfa | Other | Phase PHASE2 | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT06075537 |
| DNL952 | Other | Phase PHASE1 | Late-onset Pompe Disease | RECRUITING | NCT07354724 |
| tividenofusp alfa | Other | Phase PHASE2 | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT06075537 |
| DNL952 | Other | Phase PHASE1 | Late-onset Pompe Disease | RECRUITING | NCT07354724 |
| tividenofusp alfa | Other | Phase PHASE2 | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT06075537 |
| Placebo | Other | Phase PHASE1 | Parkinson Disease | COMPLETED | NCT03710707 |
| DNL201 | Other | Phase PHASE1 | Parkinson Disease | COMPLETED | NCT03710707 |
| Placebo | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT03757325 |
| DNL747 | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT03757325 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04551534 |
| DNL201 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04551534 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04581772 |
| DNL343 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04581772 |
| [14C] BIIB122 ([14C] DNL151) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05005338 |
| BIIB122 (DNL151) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05005338 |
| [14C] BIIB122 ([14C] DNL151) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05119790 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04268784 |
| DNL343 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04268784 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04557800 |
| DNL151 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04557800 |
| Placebo | Other | Phase PHASE1 | Healthy Participant | COMPLETED | NCT05450549 |
| DNL919 | Other | Phase PHASE1 | Healthy Participant | COMPLETED | NCT05450549 |
| No Intervention | Other | Preclinical | Mucopolysaccharidosis II | COMPLETED | NCT04007536 |
| [14C]-DNL343 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06281158 |
| BIIB122-Matching Placebo | Other | Phase PHASE3 | Parkinson Disease | TERMINATED | NCT05418673 |
| BIIB122 | Other | Phase PHASE3 | Parkinson Disease | TERMINATED | NCT05418673 |
| Placebo | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT05006352 |
| DNL343 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT05006352 |
| No intervention | Other | Preclinical | Mucopolysaccharidosis III-A | COMPLETED | NCT05523206 |
| idursulfase | Other | Phase PHASE2 | Mucopolysaccharidosis II | RECRUITING | NCT05371613 |
| tividenofusp alfa | Other | Phase PHASE2 | Mucopolysaccharidosis II | RECRUITING | NCT05371613 |
| tividenofusp alfa | Other | Phase PHASE1 | Mucopolysaccharidosis II | ACTIVE_NOT_RECRUITING | NCT04251026 |
| BIIB122-Matching Placebo | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT05348785 |
| BIIB122 | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT05348785 |
| DNL126 | Other | Phase PHASE1 | Mucopolysaccharidosis Type IIIA | ACTIVE_NOT_RECRUITING | NCT06181136 |
| Placebo | Other | Phase PHASE1 | Frontotemporal Dementia | ACTIVE_NOT_RECRUITING | NCT05262023 |
| DNL593 | Other | Phase PHASE1 | Frontotemporal Dementia | ACTIVE_NOT_RECRUITING | NCT05262023 |
| DNL952 | Other | Phase PHASE1 | Late-onset Pompe Disease | NOT_YET_RECRUITING | NCT07354724 |
| Matching Placebo | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT05842941 |
| DNL343 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT05842941 |
| BIIB122-Matching Placebo | Other | Phase PHASE2 | Parkinson Disease | RECRUITING | NCT06602193 |
| BIIB122 225 mg | Other | Phase PHASE2 | Parkinson Disease | RECRUITING | NCT06602193 |
| Placebo | Other | Phase PHASE1 | Alzheimer Disease, Early Onset | RECRUITING | NCT07328451 |
| DNL628 | Other | Phase PHASE1 | Alzheimer Disease, Early Onset | RECRUITING | NCT07328451 |
| tividenofusp alfa | Other | Phase PHASE2 | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT06075537 |
| tividenofusp alfa | Other | Phase PHASE2 | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT06075537 |
| tividenofusp alfa | Other | Phase PHASE2 | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT06075537 |
| tividenofusp alfa | Other | Phase PHASE2 | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT06075537 |
| tividenofusp alfa | Other | Phase PHASE2 | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT06075537 |
| tividenofusp alfa | Other | Phase PHASE2 | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT06075537 |
| tividenofusp alfa | Other | Phase PHASE2 | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT06075537 |
| tividenofusp alfa | Other | Phase PHASE2 | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT06075537 |
| DNL952 | DRUG | Phase PHASE1 | Late-onset Pompe Disease | NOT_YET_RECRUITING | NCT07354724 |
| DNL628 | DRUG | Phase PHASE1 | Alzheimer Disease, Early Onset | RECRUITING | NCT07328451 |
| BIIB122 225 mg | DRUG | Phase PHASE2 | Parkinson Disease | RECRUITING | NCT06602193 |
| [14C]-DNL343 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06281158 |
| DNL126 | DRUG | Phase PHASE1 | Mucopolysaccharidosis Type IIIA | ACTIVE_NOT_RECRUITING | NCT06181136 |
| Matching Placebo | DRUG | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT05842941 |
| No intervention | OTHER | Preclinical | Mucopolysaccharidosis III-A | COMPLETED | NCT05523206 |
| DNL919 | DRUG | Phase PHASE1 | Healthy Participant | COMPLETED | NCT05450549 |
| idursulfase | DRUG | Phase PHASE2 | Mucopolysaccharidosis II | RECRUITING | NCT05371613 |
| BIIB122-Matching Placebo | OTHER | Phase PHASE2 | Parkinson Disease | RECRUITING | NCT06602193 |
| BIIB122 | DRUG | Phase PHASE3 | Parkinson Disease | TERMINATED | NCT05418673 |
| DNL593 | DRUG | Phase PHASE1 | Frontotemporal Dementia | ACTIVE_NOT_RECRUITING | NCT05262023 |
| [14C] BIIB122 ([14C] DNL151) | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05119790 |
| BIIB122 (DNL151) | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05005338 |
| DNL151 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04557800 |
| DNL343 | DRUG | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT05842941 |
| tividenofusp alfa | DRUG | Phase PHASE2 | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT06075537 |
| No Intervention | OTHER | Preclinical | Mucopolysaccharidosis II | COMPLETED | NCT04007536 |
| DNL747 | DRUG | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT03757325 |
| Placebo | DRUG | Phase PHASE1 | Alzheimer Disease, Early Onset | RECRUITING | NCT07328451 |
| DNL201 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04551534 |